2025
/
08
/
27
JIC Venture Growth Investments (VGI), through its JIC Venture Growth Fund 2, has invested in CaTe, Inc. (CaTe)
Heart disease is the second leading cause of death in Japan, with 230,000 deaths annually. The mortality rate due to recurrence after discharge is 14.2% (1 in 7), and the re-hospitalization rate is 29.4% (1 in 3), highlighting the importance of post-discharge prognosis management. However, the participation rate in cardiac rehabilitation, which is an established effective treatment, is only 7% in Japan, indicating a need for improvement in the healthcare system.
CaTe, established by a cardiologist at Fujita Health University, conducts research and development digital therapeutics for cardiac rehabilitation. CaTe's unique feature is its ability to provide cardiac rehabilitation through upright exercise, eliminating the need for ergometers or other traditional devices. That means that adequate cardiac rehabilitation can be performed, even in a limited space like a home.
The purpose of this investment is to support a startup that originated in Japanese academia, Fujita Health University, and to allow heart disease patients to enjoy a longer, healthier life. VGI also expects that the recurrence after discharge and the re-hospitalization rate reduced by the diffusion of CaTe’s digital therapeutics will lead the reduction in heart disease related medical costs (2.1 trillion-yen annual basis) in Japan.
The information contained in this notice is current at the time of publication and subject to change without notice.
